Participated in eight market launches of customer products in 2023

The experts of Vetter Development Service accompany customer products with passion, expertise, and high-quality equipment through the clinical phases. © Vetter Pharma International GmbH

The experts of Vetter Development Service accompany customer products with passion, expertise, and high-quality equipment through the clinical phases. © Vetter Pharma International GmbH

– Balance Sheet 2023: Vetter successfully brings eight customer products to market
– As a market leader in Fill & Finish, the reliable service provider has established itself in early and late-phase drug development
– Vetter supports customers with medications in clinical phases through strategic consulting and extensive experience on their way to market launch

Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), reports a successful balance sheet for 2023 with eight market launches of complex customer products. The products were accompanied and supported throughout their development phases by the comprehensive services of Vetter Development Service. The medicines now on the global market are used, among other things, in oncology as well as for the treatment of autoimmune and cardiovascular diseases. Their properties and applications are very diverse, ranging from emergency medications to long-term and life-improving therapies for patients. The modes of administration also vary, from self-administration in home care to use by medical professionals.

“Bringing a promising therapy through the clinical phases to market launch is a demanding process, culminating in years of development work,” explains Dr. Claus Feussner, Senior Vice President of Vetter Development Service. “Our holistic offerings of development services are interconnected and build on each other,” he says. “This allows us to support our customers' products throughout the entire development cycle until they reach commercial market readiness and beyond. In the past five years, we have supported more than 50 market launches with our tailored services.”

Vetter has significantly expanded its clinical service portfolio in recent years, both in terms of production and personnel capacities as well as analytical services. The Vetter Development Service is one of the three pillars of the CDMO and complements commercial aseptic manufacturing as well as the assembly and packaging of injection systems. The pharmaceutical service provider currently manages more than 200 projects in early and late clinical phases as well as within the product lifecycle. With its two specialized production sites in Skokie, Illinois, USA, and Rankweil, Vorarlberg, Austria, Vetter supports the manufacturing of clinical trial samples for phases I and II. The late clinical development phase, including process design, method transfer, and handover to quality and production for commercial manufacturing and market launch, takes place in Ravensburg.